How to cite item

EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population

   
@article{JTD356,
	author = {Cesare Gridelli and Antonio Rossi},
	title = {EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population},
	journal = {Journal of Thoracic Disease},
	volume = {4},
	number = {2},
	year = {2012},
	keywords = {},
	abstract = {Activating epidermal growth factor receptor (EGFR) mutations represent the first target for which specific tyrosine kinase inhibitors (TKIs) are clinically available for the personalized treatment of advanced non-small cell lung cancer (NSCLC) patients. Until few months ago, three randomized phase III studies investigated the role of two EGFR-TKIs inhibitors, gefitinib (1-3) and erlotinib (4), as first-line treatment compared with standard platinum-based chemotherapy, in patients affected by advanced NSCLC harboring EGFR activating mutations. In all these trials the main endpoint was reached with EGFR-TKIs reporting a significant improvement in progression-free survival (PFS) and overall response rate (ORR).},
	issn = {2077-6624},	url = {https://jtd.amegroups.org/article/view/356}
}